A phase 2, prospective, randomized, open-label study of defibrotide added to standard-of-care prophylaxis for the prevention of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. - Université de Lille Accéder directement au contenu
Article Dans Une Revue Haematologica Année : 2022

A phase 2, prospective, randomized, open-label study of defibrotide added to standard-of-care prophylaxis for the prevention of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.

M. Hudspeth
  • Fonction : Auteur
S. Mori
  • Fonction : Auteur
D. Nachbaur
  • Fonction : Auteur
J. A. Perez-Simon
  • Fonction : Auteur
F. Stölzel
  • Fonction : Auteur
M. Riches
  • Fonction : Auteur
W. Wu
  • Fonction : Auteur
P. Zhang
  • Fonction : Auteur
S. Agarwal
  • Fonction : Auteur

Résumé

Acute graft-versus-host disease (aGvHD) is a life-threatening complication typically occurring within 100 days after allogeneic hematopoietic cell transplantation (allo-HCT). This hypothesis-generating, phase II, prospective, open-label, randomized study (clinicaltrials gov. Identifier: NCT03339297) compared defibrotide added to standard-of-care (SOC) GvHD prophylaxis (defibrotide prophylaxis arm) versus SOC alone (SOC arm) to prevent aGvHD post-transplant. This study estimated incidences of aGvHD and was not statistically powered to assess differences among treatment arms. Patients were randomized 1:1 to defibrotide prophylaxis arm (n=79; median age 57 years; range, 2-69 years) or SOC arm (n=73; median age 56 years; range, 2-72 years). Patient demographics in the two arms were similar except for conditioning regimen type (myeloablative: defibrotide, 76% vs. SOC, 61%) and stem cell source for allo-HCT (bone marrow: defibrotide, 34% vs. SOC, 26%). In the intent-to-treat primary endpoint analysis, the cumulative incidence of grade B-D aGvHD at day 100 post-transplant was 38.4% in the defibrotide prophylaxis arm versus 47.1% in the SOC arm (difference: –8.8%, 90% confidence interval [CI]: –22.5 to 4.9). The difference noted at day 100 became more pronounced in a subgroup analysis of patients who received antithymocyte globulin (defibrotide: 30.4%, SOC: 47.6%; difference: –17.2%; 90% CI: –41.8 to 7.5). Overall survival rates at day 180 post-transplant were similar between arms, as were the rates of serious treatment-emergent adverse events (defibrotide: 42%, SOC: 44%). While the observed differences in endpoints between the two arms were not substantial, these results suggest defibrotide prophylaxis may add a benefit to currently available SOC to prevent aGvHD following allo-HCT without adding significant toxicities.
Fichier principal
Vignette du fichier
10904-Article Text-79830-2-10-20230329.pdf (842.92 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04502776 , version 1 (13-03-2024)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

M. Hudspeth, S. Mori, D. Nachbaur, J. A. Perez-Simon, F. Stölzel, et al.. A phase 2, prospective, randomized, open-label study of defibrotide added to standard-of-care prophylaxis for the prevention of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.. Haematologica, 2022, Haematologica, 108, ⟨10.3324/haematol.2022.281471⟩. ⟨hal-04502776⟩

Collections

RIIP UNIV-LILLE
10 Consultations
2 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More